McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan is quoted in a February 6, 2014 edition of Northwestern University’s Medill Reports Chicago in an article entitled, “New class of affordable drugs caught in naming debate.” Pharmaceutical company representatives, health insurers and consumer advocates have begun discussions to sort out a years-long controversy on how to name a new class of generic biotech drugs for diseases like cancer and auto-immune disorders. View the article